| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802327001016 | 232700101 | ULTIVA PD.CSO.J.F 1MG/VIAL BTx5 VIALS | 10.47 | 10.98 | 15.13 |
| 05/2018 | 2802327002013 | 232700201 | ULTIVA PD.CSO.J.F 2MG/VIAL BTx 5 VIALS | 14.85 | 15.58 | 21.47 |
| 05/2018 | 2802327003010 | 232700301 | ULTIVA PD.CSO.J.F 5MG/VIAL BTx5VIALS | 45.92 | 48.17 | 66.38 |
For use during the induction and maintenance of general anesthesia.
Remifentanil is a µ-opioid agonist with rapid onset and peak effect, and short duration of action. The µ-opioid activity of remifentanil is antagonized by opioid antagonists such as naloxone.
1-20 minutes
Remifentanil is an esterase-metabolized opioid. The carboxylic acid metabolite is essentially inactive (1/4600 as potent as remifentanil in dogs) and is excreted by the kidneys with an elimination half-life of approximately 90 minutes.
* 350 mL/kg * 452 ± 144 mL/kg [neonates] * 223 ± 30.6 mL/kg [adolescents]
* 40 mL/min/kg [young, healthy adults]